January 28, 2022
Video
In this companion article, Dr. Lowell L. Hart shares key insights into how trilaciclib has begun to impact the management of chemotherapy-induced myelosuppression in patients with SCLC.
December 22, 2021
Video
In the second interview of the series, Dr. Lowell L. Hart of Florida Cancer Specialists & Research Institute considers the impact of chemotherapy-induced myelosuppression in small cell lung cancer and examines how trilaciclib fits into the current treatment landscape.
August 27, 2019
Video
Lowell L. Hart, MD, FACP, scientific director of clinical research, Florida Cancer Specialists, and associate professor of medicine, Wake Forest University School of Medicine, discusses the effect of CDK4/6 inhibitor, trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer receiving topotecan. Hart presented the phase II results from the blinded, multicenter study during the 2019 ASCO Annual Meeting.